111 related articles for article (PubMed ID: 10945003)
1. [Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
Negoro S; Masuda N
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1105-8. PubMed ID: 10945003
[TBL] [Abstract][Full Text] [Related]
2. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Goto K; Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Matsumoto T; Ohmatsu H; Niho S; Kodama T; Shinkai T; Tamura T; Ohe Y; Kunitoh H; Yamamoto N; Nokihara H; Yoshida K; Sugiura T; Matsui K; Saijo N
Br J Cancer; 2004 Aug; 91(4):659-65. PubMed ID: 15280919
[TBL] [Abstract][Full Text] [Related]
4. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Choi HJ; Cho BC; Shin SJ; Cheon SH; Jung JY; Chang J; Kim SK; Sohn JH; Kim JH
Cancer Chemother Pharmacol; 2008 Feb; 61(2):309-13. PubMed ID: 17576560
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Kudoh S; Nakamura S; Nakano T; Komuta K; Isobe T; Katakami N; Fukuda Y; Takada Y; Takada M; Fukuoka M; Ariyoshi Y
Lung Cancer; 2005 Aug; 49(2):263-9. PubMed ID: 16022921
[TBL] [Abstract][Full Text] [Related]
6. [Pilot study of cisplatin, ifosfamide and irinotecan (CPT-11) with granulocyte colony-stimulating factor support (CIC-regimen) in relapsed small-cell lung cancer].
Fujita A; Takabatake H; Tagaki S; Sekine K
Gan To Kagaku Ryoho; 1998 Apr; 25(5):761-4. PubMed ID: 9571978
[No Abstract] [Full Text] [Related]
7. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Hirose T; Horichi N; Ohmori T; Ogura K; Hosaka T; Ando K; Ishida H; Noguchi H; Adachi M
Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of small cell lung cancer].
Negoro S
Gan To Kagaku Ryoho; 2005 Jun; 32(6):777-82. PubMed ID: 15984515
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study.
Ichiki M; Gohara R; Rikimaru T; Kitajima T; Fujiki R; Shimada A; Aizawa H
Chemotherapy; 2003 Jul; 49(4):200-5. PubMed ID: 12886056
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Rocha-Lima CM; Herndon JE; Lee ME; Atkins JN; Mauer A; Vokes E; Green MR;
Ann Oncol; 2007 Feb; 18(2):331-7. PubMed ID: 17065590
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.
Naka N; Kawahara M; Okishio K; Hosoe S; Ogawara M; Atagi S; Takemoto Y; Ueno K; Kawaguchi T; Tsuchiyama T; Furuse K
Lung Cancer; 2002 Sep; 37(3):319-23. PubMed ID: 12234702
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan in small-cell lung cancer--Japanese trials.
Fukuoka M; Masuda N; Kudoh S; Negoro S
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):57-62. PubMed ID: 10981292
[TBL] [Abstract][Full Text] [Related]
15. Small-cell lung cancer: current therapy and novel agents.
Horiike A; Saijo N
Oncology (Williston Park); 2005 Jan; 19(1):47-52; discussion 52, 54-8. PubMed ID: 15743151
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
Fennell DA; Steele JP; Shamash J; Slater SE; Sheaff MT; Wells P; Rudd RM; Stebbing J
Int J Cancer; 2007 Dec; 121(11):2575-7. PubMed ID: 17680556
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.
Jacot W; Pujol JL; Chakra M; Molinier O; Bozonnat MC; Gervais R; Quantin X
Lung Cancer; 2012 Feb; 75(2):213-6. PubMed ID: 21831476
[TBL] [Abstract][Full Text] [Related]
18. Progress in treatment of small-cell lung cancer: role of CPT-11.
Saijo N
Br J Cancer; 2003 Dec; 89(12):2178-83. PubMed ID: 14676791
[TBL] [Abstract][Full Text] [Related]
19. Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
Sekine I; Nokihara H; Takeda K; Nishiwaki Y; Nakagawa K; Isobe H; Mori K; Matsui K; Saijo N; Tamura T
Br J Cancer; 2008 Feb; 98(4):693-6. PubMed ID: 18253118
[TBL] [Abstract][Full Text] [Related]
20. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.
Batist G; Carney DN; Cowan KH; Veach SR; Gilliom M; Bunn PA; Ihde DC
J Clin Oncol; 1986 Jun; 4(6):982-6. PubMed ID: 3012008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
